Pacira Pharmaceuticals Inc (PCRX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 71.09% | 67.99% | 66.08% | 65.40% | 68.22% | 72.72% | 73.68% | 74.88% | 74.10% | 72.25% | 73.03% | 72.72% | 72.69% | 72.94% | 73.98% | 74.93% | 74.65% | 74.91% | 74.35% | 74.22% |
| Operating profit margin | 13.73% | 7.18% | 7.79% | 6.45% | 9.57% | 11.46% | 13.83% | 15.23% | 16.61% | 21.24% | 18.54% | 11.17% | 10.79% | 6.95% | 3.45% | 6.09% | 2.49% | 5.34% | 6.08% | 6.76% |
| Pretax margin | 9.66% | 1.60% | -0.75% | -3.34% | 2.12% | 3.89% | 7.77% | 8.83% | 10.42% | 15.31% | 11.70% | 5.57% | 4.67% | 0.91% | -1.97% | 0.09% | -2.54% | 0.29% | 1.67% | 2.18% |
| Net profit margin | 6.57% | 1.12% | -0.74% | -1.70% | 2.54% | 3.23% | 6.44% | 6.66% | 7.75% | 12.53% | 35.59% | 33.88% | 33.87% | 29.95% | -2.47% | -0.02% | -2.62% | 0.55% | 2.04% | 2.10% |
Over the past eight quarters, Pacira BioSciences Inc has demonstrated healthy gross profit margins, ranging from 68.65% to 73.90%. This suggests that the company efficiently manages its production costs and pricing strategies to generate profits from its core operations.
However, the operating profit margin has been more volatile, fluctuating between 8.70% and 22.96%. The downward trend since Q3 2022 indicates that the company may be experiencing challenges in controlling its operating expenses and improving operational efficiency.
Similarly, the pretax margin and net profit margin have also shown fluctuations. The pretax margin has varied from -3.06% to 9.14%, indicating fluctuations in the company's ability to generate profits before accounting for tax expenses. The net profit margin, ranging from -1.56% to 6.62%, reflects Pacira BioSciences' ability to generate profits after all expenses, including taxes.
Overall, while Pacira BioSciences has maintained a relatively strong gross profit margin, the declining trend in operating profit margin and volatility in pretax and net profit margins suggest the company may face challenges in controlling costs and maintaining profitability in the long run. Further analysis of the company's cost structure and revenue streams may provide insights into potential areas for improvement.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.57% | 2.91% | 3.12% | 2.60% | 3.57% | 4.27% | 4.86% | 4.65% | 4.33% | 7.71% | 6.84% | 3.78% | 3.64% | 2.40% | 1.62% | 3.23% | 1.26% | 2.60% | 2.88% | 3.33% |
| Return on assets (ROA) | 2.66% | 0.46% | -0.30% | -0.69% | 0.95% | 1.20% | 2.26% | 2.03% | 2.02% | 4.54% | 13.13% | 11.47% | 11.42% | 10.34% | -1.16% | -0.01% | -1.33% | 0.27% | 0.97% | 1.03% |
| Return on total capital | 5.93% | 2.81% | 2.22% | 1.44% | 3.72% | 4.35% | 5.69% | 5.98% | 6.28% | 9.93% | 8.47% | 5.26% | 4.90% | 2.73% | 2.19% | 3.54% | 1.96% | 3.78% | 4.58% | 4.87% |
| Return on equity (ROE) | 4.82% | 0.84% | -0.57% | -1.36% | 2.05% | 2.71% | 5.19% | 5.42% | 5.75% | 8.58% | 25.33% | 22.70% | 23.48% | 21.57% | -2.60% | -0.02% | -3.10% | 0.62% | 2.23% | 2.27% |
Pacira BioSciences Inc's profitability ratios indicate varying levels of performance over the past eight quarters.
1. Operating return on assets (Operating ROA) has shown a relatively stable trend, ranging from 3.82% to 5.91% over the period analyzed. This metric reflects the company's ability to generate operating income from its assets.
2. Return on assets (ROA) has been volatile, with negative values in Q2 and Q1 of 2023. This suggests that the company struggled to generate profits relative to its total assets during those quarters.
3. Return on total capital remained relatively consistent, with values between 4.40% and 8.16% across the quarters. This ratio highlights how efficiently the company is utilizing its total capital to generate profits.
4. Return on equity (ROE) also exhibited fluctuations, with negative values in Q2 and Q1 of 2023. ROE ranged from -1.36% to 5.42% during the period, indicating the company's ability to generate profits for its shareholders from their investments.
Overall, while some profitability ratios show stability or improvement, others reflect volatility and potential challenges for Pacira BioSciences Inc in effectively leveraging its assets and capital to generate profits and returns for its shareholders.